Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review

Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, in EU countries, nintedanib plus docetaxel is used for patients with advanced non‐small cell lung cancer (NSCLC) after first‐line chemotherapy. Here, we report a case of advanced NSCLC in a patient wi...

Full description

Bibliographic Details
Main Authors: Toshihiro Shiratori, Hisashi Tanaka, Chiori Tabe, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Shingo Takanashi, Sadatomo Tasaka
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Thoracic Cancer
Subjects:
Idiopathic pulmonary fibrosis
lung cancer
nintedanib
Online Access:https://doi.org/10.1111/1759-7714.13437

Internet

https://doi.org/10.1111/1759-7714.13437

Similar Items